Seeking Alpha

GlaxoSmithKline (GSK +0.5%) and Theravance (THRX -1.7%) say their New Drug Application for...

GlaxoSmithKline (GSK +0.5%) and Theravance (THRX -1.7%) say their New Drug Application for UMEC/VI, a treatment for patients with chronic obstructive pulmonary disease, has been accepted by the FDA, giving it the go-ahead for a substantive review. The PDUFA goal date has also been set for December 18, 2013.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs